Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.
Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta®, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron a license to manufacture and commercialize Eureca-V™ Nuclease, the wild-type MAD7™ CRISPR Type-V nuclease.
Genome editing enzymes such as Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation.
Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo.
Aldevron has named Brian Walters, President of its antibody business unit and Tom Foti President of its protein business unit.
Ally Hauser of Aldevron has been promoted to Director of Client Relations for Protein Services. In her position, Hauser will lead new projects and initiatives to expand research grade and cGMP protein services to the benefit of our clients.
Aldevron announced today its new fermentation capacity of 1,000 liters and plans to significantly increase the Company’s manufacturing footprint in Madison, WI. The large-scale fermentation equipment is already installed and will be coming on-line in Q4 2019.
Aldevron is announcing the release of GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, the trade name for Aldevron’s research grade and GMP products, is the direct result of a partnership with Integrated DNA Technologies, Inc. (IDT). The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity.
